Abstract
Some metformin hydrochloride extended-release (MetHCl-XR) tablet products have been marketed in Indonesia with varying prices. In general, price is considered to indicates the quality of a product. This research was conducted to review the products quality, especially the dissolution rate of the products, and to find out if the price is an indicator of the product quality. Three brands of MetHCl 500 mg XR tablets were randomly selected, namely Tablet A, B, and C which the price of Tablet B > A > C, then the Tablets were characterized. The results showed that Tablet A, B, and C contain MetHCl with an average of 100.61%, 98.72%, and 101.15% respectively, and met the uniformity of dosage unit requirement. Tablet A met the requirements of dissolution tests 1, 2, 3, and 4, while Tablet B and C met the requirements of dissolution tests 1 and 3. The cumulative percentage of MetHCl release at the 10th hour of Tablet A, B, and C were 94.18%, 97.24%, and 94.59% respectively with the release kinetics of Tablet A and B following Higuchi model, whereas Tablet C following a first-order. Drug release of all tablets occurred in non-Fick diffusion. In conclusion, the three tablets met the standards required by USP 43 and the price is not an indicator of MetHCl-XR tablet products quality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
